{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T17:34:12Z","timestamp":1772386452989,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00415-025-12980-x","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T11:30:43Z","timestamp":1740223843000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A disproportionality analysis of surgical\u00a0site infections across multiple sclerosis disease\u00a0modifying therapies"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3202-6921","authenticated-orcid":false,"given":"Alexandra","family":"Balshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Dempsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nova","family":"Manning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Leuenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursela","family":"Baber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob A.","family":"Sloane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,22]]},"reference":[{"issue":"1","key":"12980_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jhin.2017.03.004","volume":"96","author":"JM Badia","year":"2017","unstructured":"Badia JM, Casey AL, Petrosillo N, Hudson PM, Mitchell SA, Crosby C (2017) Impact of surgical site infection on healthcare costs and patient outcomes: a systematic review in six European countries. J Hosp Infect 96(1):1\u201315. https:\/\/doi.org\/10.1016\/j.jhin.2017.03.004","journal-title":"J Hosp Infect"},{"issue":"Suppl 1","key":"12980_CR2","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1089\/sur.2006.7.s1-7","volume":"7","author":"WG Cheadle","year":"2006","unstructured":"Cheadle WG (2006) Risk factors for surgical site infection. Surg Infect (Larchmt) 7(Suppl 1):S7\u2013S11. https:\/\/doi.org\/10.1089\/sur.2006.7.s1-7","journal-title":"Surg Infect (Larchmt)"},{"issue":"10","key":"12980_CR3","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1136\/jnnp-2017-317493","volume":"89","author":"JMA Wijnands","year":"2018","unstructured":"Wijnands JMA, Zhu F, Kingwell E et al (2018) Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study. J Neurol Neurosurg Psychiatry 89(10):1050\u20131056. https:\/\/doi.org\/10.1136\/jnnp-2017-317493","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"12980_CR4","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.arth.2019.04.022","volume":"34","author":"ND Quinlan","year":"2019","unstructured":"Quinlan ND, Chen DQ, Werner BC, Barnes CL, Browne JA (2019) Patients with multiple sclerosis are at increased risk for postoperative complications following total hip and knee arthroplasty. J Arthroplasty 34(8):1606\u20131610. https:\/\/doi.org\/10.1016\/j.arth.2019.04.022","journal-title":"J Arthroplasty"},{"issue":"6","key":"12980_CR5","doi-asserted-by":"publisher","first-page":"0157753","DOI":"10.1371\/journal.pone.0157753","volume":"11","author":"R B\u00f6hm","year":"2016","unstructured":"B\u00f6hm R, von Hehn L, Herdegen T et al (2016) OpenVigil FDA\u2014Inspection of US American adverse drug events pharmacovigilance data and novel clinical applications. PLoS ONE 11(6):0157753. https:\/\/doi.org\/10.1371\/journal.pone.0157753","journal-title":"PLoS ONE"},{"issue":"9","key":"12980_CR6","doi-asserted-by":"publisher","first-page":"2200535","DOI":"10.2807\/1560-7917.ES.2023.28.9.2200535","volume":"28","author":"P Bischoff","year":"2023","unstructured":"Bischoff P, Kramer TS, Schr\u00f6der C et al (2023) Age as a risk factor for surgical site infections: German surveillance data on total hip replacement and total knee replacement procedures 2009 to 2018. Euro Surveill 28(9):2200535. https:\/\/doi.org\/10.2807\/1560-7917.ES.2023.28.9.2200535","journal-title":"Euro Surveill"},{"issue":"6","key":"12980_CR7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10(6):483\u2013486. https:\/\/doi.org\/10.1002\/pds.677","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"12980_CR8","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B et al (2024) The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): development and statement. Drug Saf 47(6):575\u2013584. https:\/\/doi.org\/10.1007\/s40264-024-01421-9","journal-title":"Drug Saf"},{"issue":"2","key":"12980_CR9","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2353\/ajpath.2009.080355","volume":"175","author":"Y Iwata","year":"2009","unstructured":"Iwata Y, Yoshizaki A, Komura K et al (2009) CD19, a response regulator of B lymphocytes, regulates wound healing through hyaluronan-induced TLR4 signaling. Am J Pathol 175(2):649\u2013660. https:\/\/doi.org\/10.2353\/ajpath.2009.080355","journal-title":"Am J Pathol"},{"issue":"1","key":"12980_CR10","first-page":"79","volume":"74","author":"AJ Stout","year":"1993","unstructured":"Stout AJ, Gresser I, Thompson WD (1993) Inhibition of wound healing in mice by local interferon alpha\/beta injection. Int J Exp Pathol 74(1):79\u201385","journal-title":"Int J Exp Pathol"},{"issue":"5","key":"12980_CR11","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/ana.20859","volume":"59","author":"M Niino","year":"2006","unstructured":"Niino M, Bodner C, Simard ML et al (2006) Natalizumab effects on immune cell responses in multiple sclerosis [published correction appears in Ann Neurol. 2006 Jun;59(6):990]. Ann Neurol 59(5):748\u2013754. https:\/\/doi.org\/10.1002\/ana.20859","journal-title":"Ann Neurol"},{"issue":"1","key":"12980_CR12","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1038\/s41467-018-07825-3","volume":"9","author":"Y Ovadya","year":"2018","unstructured":"Ovadya Y, Landsberger T, Leins H et al (2018) Impaired immune surveillance accelerates accumulation of senescent cells and aging. Nat Commun 9(1):5435. https:\/\/doi.org\/10.1038\/s41467-018-07825-3. (Published 2018 Dec 21)","journal-title":"Nat Commun"},{"issue":"4","key":"12980_CR13","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/ana.27026","volume":"96","author":"Y Hu","year":"2024","unstructured":"Hu Y, Frisell T, Alping P et al (2024) Hospital-treated infections and risk of disability worsening in multiple sclerosis. Ann Neurol 96(4):694\u2013703. https:\/\/doi.org\/10.1002\/ana.27026","journal-title":"Ann Neurol"},{"issue":"13 Pt 2","key":"12980_CR14","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1212\/01.wnl.0000265393.03231.e5","volume":"70","author":"MM Vellinga","year":"2008","unstructured":"Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH (2008) Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 70(13 Pt 2):1150\u20131151. https:\/\/doi.org\/10.1212\/01.wnl.0000265393.03231.e5","journal-title":"Neurology"},{"issue":"2","key":"12980_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40120-019-00160-9","volume":"8","author":"B Barry","year":"2019","unstructured":"Barry B, Erwin AA, Stevens J, Tornatore C (2019) Fingolimod rebound: a review of the clinical experience and management considerations. Neurol Ther 8(2):241\u2013250. https:\/\/doi.org\/10.1007\/s40120-019-00160-9","journal-title":"Neurol Ther"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-12980-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-12980-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-12980-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T17:42:52Z","timestamp":1742233372000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-12980-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,22]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["12980"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-12980-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,22]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A. Balshi reports no disclosures relative to the manuscript; J. Dempsey reports no disclosures relative to the manuscript; N. Manning reports no disclosures relative to the manuscript; G. Leuenberger reports no disclosures relative to the manuscript; U. Baber reports no disclosures relative to the manuscript; J.A. Sloane has grant funding from National MS Society and has consulted for Biogen, Genentech, Teva, Banner, Sanofi, and Cellgene.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"223"}}